Pfizer and Bristol-Myers Squibb obtained approval from Japanese regulators to market the anticoagulant Eliquis, or apixaban, for ischemic stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation. The approval was based on positive results of the late-stage ARISTOTLE trial. Eliquis has also been approved in Europe and Canada.

Related Summaries